MA54223A - Dérivés de 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one servant d'inhibiteurs de hpk1 pour le traitement du cancer - Google Patents

Dérivés de 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one servant d'inhibiteurs de hpk1 pour le traitement du cancer

Info

Publication number
MA54223A
MA54223A MA054223A MA54223A MA54223A MA 54223 A MA54223 A MA 54223A MA 054223 A MA054223 A MA 054223A MA 54223 A MA54223 A MA 54223A MA 54223 A MA54223 A MA 54223A
Authority
MA
Morocco
Prior art keywords
pyrrolo
pyridin
dihydro
cancer
treatment
Prior art date
Application number
MA054223A
Other languages
English (en)
Other versions
MA54223B1 (fr
Inventor
Omar Khaled Ahmad
Bel Matthew L Del
Rebecca Anne Gallego
Mingying He
Mehran Jalaie
Ted William Johnson
Robert Steven Kania
Michele Ann Mctigue
Sajiv Krishnan Nair
Anne-Marie Dechert Schmitt
Jamison Bryce Tuttle
Dahui Zhou
Ru Zhou
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Priority claimed from PCT/IB2019/059702 external-priority patent/WO2020100027A1/fr
Publication of MA54223A publication Critical patent/MA54223A/fr
Publication of MA54223B1 publication Critical patent/MA54223B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA54223A 2018-11-15 2019-11-12 Dérivés de 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one en tant qu'inhibiteurs de hpk1 pour le traitement du cancer MA54223B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862767602P 2018-11-15 2018-11-15
PCT/IB2019/059702 WO2020100027A1 (fr) 2018-11-15 2019-11-12 Dérivés de 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one servant d'inhibiteurs de hpk1 pour le traitement du cancer

Publications (2)

Publication Number Publication Date
MA54223A true MA54223A (fr) 2022-02-23
MA54223B1 MA54223B1 (fr) 2023-10-31

Family

ID=77369712

Family Applications (1)

Application Number Title Priority Date Filing Date
MA54223A MA54223B1 (fr) 2018-11-15 2019-11-12 Dérivés de 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one en tant qu'inhibiteurs de hpk1 pour le traitement du cancer

Country Status (2)

Country Link
AR (1) AR117073A1 (fr)
MA (1) MA54223B1 (fr)

Also Published As

Publication number Publication date
MA54223B1 (fr) 2023-10-31
AR117073A1 (es) 2021-07-07

Similar Documents

Publication Publication Date Title
MA43745A (fr) Dérivés de 4,6-dihydropyrrolo[3,4-c]pyrazole-5(1h)-carbonitrile pour le traitement du cancer
EP3781564C0 (fr) Dérivés de pyridazine pour le traitement du cancer
ZA202103099B (en) 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer
MA45146A (fr) Dérivés de pyrazolopyridine pour le traitement du cancer
MA43746A (fr) Dérivés de 2-cyanoisoindoline pour le traitement du cancer
MX2018005694A (es) 2- (1h-indazol-3-il) -3h-imidazo[4,5-c] piridinas y usos antiinflamatorios de las mismas.
PH12018500587A1 (en) Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer
MX384948B (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos.
MX384905B (es) Degradadores de proteínas de bromodominio y dominioextraterminal (bet).
HK1246286A1 (zh) Lrrk2抑制剂及其制备和使用方法
MA41251B1 (fr) Dérivés de thiéno[2,3-c]pyrrol-4-one comme inhibiteurs erk
EA201791692A1 (ru) 4H-ПИРРОЛО[3,2-c]ПИРИДИН-4-ОНОВЫЕ ПРОИЗВОДНЫЕ
EA202090371A1 (ru) 1H-ПИРРОЛО[2,3-c]ПИРИДИН-7(6H)-ОНЫ И ПИРАЗОЛО[3,4-c]ПИРИДИН-7(6H)-ОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ БЕЛКОВ BET
MA51139A (fr) Dérivés de 1-(pipéridinocarbonylméthyl)-2-oxopipérazine pour le traitement du cancer
ME03374B (fr) Dérivés 5-[(pipérazine-1-yl) -3-oxo-propyl]-imidazolidine -2,4-dione comme inhibiteurs d'adamts pour le traitement de l'arthrose
EP3697452A4 (fr) Vecteurs lentiviraux pour l'administration de pklr pour traiter une déficience en pyruvate kinase
EP3947460A4 (fr) Agents multispécifiques pour le traitement du cancer
EP3454896A4 (fr) Dérivés hétérocycliques pour le traitement de rsv
EP3630080A4 (fr) Utilisation d'inhibiteurs de ezh2 pour le traitement du cancer
PH12020552059A1 (en) Dosing regimen for the treatment of pi3k related disorders
EP3866780C0 (fr) Dérivés de flavagline pour inhiber l'activation de l'oncogène kras
EP3400942A4 (fr) Utilisation de dérivés de quinoléine pour le traitement du cancer de l' sophage et procédé de traitement, composition pharmaceutique et trousse associée
PL3894411T3 (pl) Pochodne 7-fenoksy-N-(3-azabicyklo[3.2.1]oktan-8-ylo)-6,7-dihydro-5H-pirolo[1,2-b][1,2,4]triazolo-2-aminy i związki pokrewne jako modulatory gamma-sekretazy do leczenia choroby Alzheimera
EA201991355A1 (ru) Производные имидазо[1,5-а]пиразина в качестве ингибиторов pi3kдельта
IL288408A (en) Methods of treating urinary system cancers